<?xml version="1.0" encoding="UTF-8"?>
<p>The evaluated compounds were approved drugs, currently on the market with the exception of four compounds which were under phase III trial (
 <xref rid="molecules-25-02529-t004" ref-type="table">Table 4</xref>). There are several compounds among the most promising ones, which are characterized as well-tolerated or having no side effects, such as danoprevir and sovaprevir of the HCV protease inhibitors, teneligliptin and gemigliptin but also trelagliptin, evogliptin and gosogliptin among the DPP-4 inhibitors, inogatran and melagatran of Î±-thrombin inhibitors.
</p>
